Cohen addresses the three-pronged parts of drug development process or clinical trials
Quintiles released the written remarks, its Senior Vice President and Global Head of Early Clinical Development, Oren Cohen, MD, will make today October 9, to a Congressional Roundtable being held in Research Triangle Park, NC. The roundtable is an outgrowth of the U.S. House Energy & Commerce Committee’s 21st Century Cures Initiative and will focus on the discovery, development, and delivery of vaccines.
In these remarks, again specific to vaccines, Cohen addresses the three-pronged parts of drug development process or clinical trials; pathways or regulatory alternatives to minimize clinical development times, and preparedness for development of vaccines.
Under clinical trials or process, interestingly, Cohen targets ECs and IRB inefficiencies, promotes eSource Data Capture and the enforced use of common data standards, such as those created by CDISC.
Under pathways, Cohen believes an adaptive licensing approach similar to the EMA pilots now underway, would be helpful for FDA in regard to vaccine development.
Dr. Cohen is an infectious diseases expert and head’s Quintiles’ Phase I Clinical Research division, which includes world-class facilities in Overland Park, Kansas (US) and London.
Read the full release here.
The following infographic was sent with the press release. (Click to enlarge).
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.